Summary & Overview
HCPCS J7680: Terbutaline Inhalation Solution, Compounded, DME
HCPCS Level II code J7680 represents compounded terbutaline sulfate inhalation solution in a concentrated form, billed per milligram for administration through durable medical equipment. This code covers a specialized inhalation medication prepared by a compounding pharmacy or supplier and delivered for use with home nebulizers or other DME delivery systems. Nationally, the code matters because it addresses coverage and billing for compounded respiratory therapies used in outpatient and home care settings, impacting pharmacy, DME suppliers, and payers handling specialty inhalation treatments.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn how J7680 is defined clinically and operationally, the typical sites of service associated with this inhalation DME therapy, and what documentation and billing context are commonly relevant. The publication provides benchmarks and policy context where available, outlines common billing practices for compounded inhalation solutions administered via DME, and summarizes clinical context for terbutaline use in respiratory care. Data not available in the input where specific utilization, coding variants, or associated ICD-10 diagnoses would normally be detailed.
Billing Code Overview
HCPCS Level II code J7680 describes terbutaline sulfate inhalation solution, compounded product, concentrated form, administered through durable medical equipment (DME), billed per milligram. The service type is compounded inhalation medication administration via DME, reflecting a pharmacist- or compounding-provider-prepared inhalation solution delivered and used with home nebulizer equipment or other DME delivery systems. The typical site of service is home or other outpatient setting where DME is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute bronchospasm from asthma or chronic obstructive pulmonary disease (COPD) experiencing wheezing and dyspnea not relieved by baseline inhalers. A pulmonology clinic or an emergency department evaluates the patient, confirms bronchospasm with exam and pulse oximetry, and elects to administer racemic or nebulized bronchodilator therapy using a compounded terbutaline sulfate inhalation solution delivered via a durable medical equipment (DME) nebulizer. The DME is set up by respiratory therapy or trained nursing staff; medication is compounded to the prescribed concentration and dose (billed per mg using J7680), labeled, and administered. The workflow includes medication order entry, pharmacy compounding and verification, delivery through the facility DME, administration and monitoring for response and adverse effects (heart rate, blood pressure, oxygen saturation), documentation of drug, dose (mg), route (inhalation), time, and signer credentials. Typical follow-up includes reassessment for symptom relief, possible repeat dosing, and discharge instructions or admission if deterioration occurs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard claim billing | Use for routine billing when no special modifier applies |